Corvas, Vascular Genomics Inc. deal

CVAS received a three-year option to acquire Vascular Genomics, a privately held company that develops vascular targeting technology. CVAS would make the purchase with

Read the full 245 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE